Response Genetics, Inc.

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer based on its technologies. The Company generates revenues primarily from sales of its analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. During the fiscal year ended December 31, 2008 (fiscal 2008), the Company launched its diagnostic tests under the brand name ResponseDx for non small cell lung cancer and colon cancer.Using its technologies, the Company extracts nucleic acids, such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE), specimens and analyze genetic information contained in these tissues. The Company generates clinically relevant information regarding the risks of recurrence of cancer or chemotherapy response using approximately 30,000 genes available from microarray profiling of FFPE specimens. 
 
     

查看其它语言版本

新闻

1月7日澳洲股市:对铁矿石价格乐观

🕔1/7/2010 9:30:30 AM 15192

周三澳洲股市收市平淡,受银行股拖累,下午的盘面回吐出早先的涨幅。由于投资者对铁矿石价格乐观,矿业股上涨。收盘时基准指数S&P/ASX200上涨1.6 点,报4925.9 点; 综合指数上涨7.7 点, 或0.15%, 报4947.2点。

阅读全文
###

41,308 公司背景浏览

  • 本页浏览人次: (过去7日: 8) (过去30日: 44) (自发布以来: 7375) 

公司详细信息